Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Rating) in a research note published on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

EVOK opened at $0.39 on Monday. The company has a quick ratio of 7.38, a current ratio of 7.51 and a debt-to-equity ratio of 1.41. Evoke Pharma has a 52-week low of $0.36 and a 52-week high of $1.91. The company has a 50 day moving average of $0.54 and a two-hundred day moving average of $0.76. The company has a market cap of $12.84 million, a P/E ratio of -1.50 and a beta of 0.77.

Evoke Pharma (NASDAQ:EVOK – Get Rating) last released its quarterly earnings data on Tuesday, March 8th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 154.99% and a negative net margin of 529.48%. The business had revenue of $0.36 million for the quarter.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in shares of Evoke Pharma during the fourth quarter worth $25,000. Virtu Financial LLC lifted its position in shares of Evoke Pharma by 192.5% during the fourth quarter. Virtu Financial LLC now owns 55,336 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 36,418 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Evoke Pharma during the first quarter worth $139,000. BlackRock Inc. lifted its position in shares of Evoke Pharma by 9.2% during the third quarter. BlackRock Inc. now owns 175,559 shares of the specialty pharmaceutical company’s stock worth $228,000 after purchasing an additional 14,789 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Evoke Pharma by 19.7% during the third quarter. Geode Capital Management LLC now owns 234,309 shares of the specialty pharmaceutical company’s stock worth $304,000 after purchasing an additional 38,549 shares in the last quarter. 12.88% of the stock is currently owned by institutional investors and hedge funds.

About Evoke Pharma (Get Rating)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.

Further Reading